Incannex Healthcare (IXHL) closed at $2.64 on October 23, 2026, up 1.5% from the previous close, on volume of 34,401 shares (30-day average 83,186).
Data as of October 23, 2026.
23-Oct-2026
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Globe Newswire (Tue, 25-Aug 8:46 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
IXHL’s $10M Direct Offering Fuels Key Phase 2 Trials, Lowers Dilution Risk
Market Chameleon (Thu, 12-Mar 4:13 AM ET)
FDA Fast Track Status Propels IXHL’s Lead Drug IHL-42X for Obstructive Sleep Apnea
Market Chameleon (Wed, 3-Dec 6:14 AM ET)
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
Incannex Healthcare trades on the NASDAQ stock market under the symbol IXHL.
As of October 23, 2026, IXHL stock price climbed to $2.64 with 34,401 million shares trading.
IXHL has a beta of 2.26, meaning it tends to be more sensitive to market movements. IXHL has a correlation of 0.08 to the broad based SPY ETF.
IXHL has a market cap of $33.12 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IXHL traded as high as $380.40 and as low as $2.40.
IXHL has underperformed the market in the last year with a price return of -74.2% while the SPY ETF gained +14.3%. IXHL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.5% and -14.8%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
IXHL support price is $2.51 and resistance is $2.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IXHL shares will trade within this expected range on the day.
